# Efficacy and Safety of EsoDuo®

> **NCT06430047** · PHASE4 · RECRUITING · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 180 (estimated)

## Conditions studied

- Gastro Esophageal Reflux

## Interventions

- **DRUG:** EsoDuo® Tablet

## Key facts

- **NCT ID:** NCT06430047
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-25
- **Primary completion:** 2025-01
- **Final completion:** 2025-05
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06430047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06430047, "Efficacy and Safety of EsoDuo®". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06430047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*